Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Net Cash Flow of -$336.8 million for Q1 2026, up 60.93% year-over-year from -$209.3 million in Q1 2025, and down 278.97% quarter-over-quarter from $188.2 million in Q4 2025.
Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$336.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 60.93% year-over-year to -$336.8 million; the TTM figure through Mar 2026 stood at $221.1 million (up 218.62% YoY), while the FY2025 annual figure was -$304.2 million, down 145.09% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$336.8 million, down from $188.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $905.2 million in Q4 2024, with the low at -$882.0 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$71.8 million (2022), against an average of -$96.9 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 873.16% in 2024, then plunged 75526.58% in 2025.
- Sarepta Therapeutics' Net Cash Flow stood at -$71.8 million in 2022, then plunged by 62.95% to -$117.1 million in 2023, then surged by 873.16% to $905.2 million in 2024, then tumbled by 79.21% to $188.2 million in 2025, then slumped by 278.97% to -$336.8 million in 2026.
- Business Quant data shows SRPT's Net Cash Flow at -$336.8 million in Q1 2026, $188.2 million in Q4 2025, and $100.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 103.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.70 Mn |
| Jun 30, 2026 | 103.70 Mn |
| Mar 31, 2026 | -336.83 Mn |
| Mar 31, 2026 | -336.83 Mn |
| Dec 31, 2025 | 188.21 Mn |
| Dec 31, 2025 | 188.21 Mn |
| Sep 30, 2025 | 100.03 Mn |
| Sep 30, 2025 | 100.03 Mn |
| Jun 30, 2025 | 269.73 Mn |
| Jun 30, 2025 | 269.73 Mn |
| Mar 31, 2025 | -862.14 Mn |
| Mar 31, 2025 | -862.14 Mn |
| Dec 31, 2024 | 905.16 Mn |
| Dec 31, 2024 | 905.16 Mn |
| Sep 30, 2024 | -185.77 Mn |
| Sep 30, 2024 | -185.77 Mn |
| Jun 30, 2024 | -43.67 Mn |
| Jun 30, 2024 | -43.67 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |